220 related articles for article (PubMed ID: 22534313)
1. Severe adalimumab-induced thrombocytopenia in a patient with Crohn's disease.
Casanova MJ; Chaparro M; Martínez S; Vicuña I; Gisbert JP
J Crohns Colitis; 2012 Dec; 6(10):1034-7. PubMed ID: 22534313
[TBL] [Abstract][Full Text] [Related]
2. Adalimumab for the treatment of pediatric Crohn's disease.
Nuti F; Fiorino G; Danese S
Expert Rev Clin Immunol; 2015; 11(9):963-72. PubMed ID: 26211396
[TBL] [Abstract][Full Text] [Related]
3. Guillain-Barrè syndrome after treatment with human anti-tumor necrosis factorα (adalimumab) in a Crohn's disease patient: case report and literature review.
Cesarini M; Angelucci E; Foglietta T; Vernia P
J Crohns Colitis; 2011 Dec; 5(6):619-22. PubMed ID: 22115384
[TBL] [Abstract][Full Text] [Related]
4. Infliximab and adalimumab-induced thrombocytopenia in a woman with colonic Crohn's disease.
Salar A; Bessa X; Muñiz E; Monfort D; Besses C; Andreu M
Gut; 2007 Aug; 56(8):1169-70. PubMed ID: 17344276
[No Abstract] [Full Text] [Related]
5. [Adalimumab for the treatment of adult Crohn's disease--update of a consensus report by the Working Group Inflammatory Bowel Disease of the Austrian Society of Gastroenterology and Hepatology].
Novacek G; Haas T; Knoflach P; Petritsch W; Tilg H; Vogelsang H; Reinisch W
Z Gastroenterol; 2013 Sep; 51(9):1101-9. PubMed ID: 23996653
[TBL] [Abstract][Full Text] [Related]
6. Acute coronary syndrome in a Crohn's disease patient treated with adalimumab.
Petitpain N; Bornert-Keller N; Peyrin-Biroulet L
J Crohns Colitis; 2013 Oct; 7(9):e396. PubMed ID: 23523265
[No Abstract] [Full Text] [Related]
7. Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn's disease.
Watanabe M; Hibi T; Mostafa NM; Chao J; Arora V; Camez A; Petersson J; Thakkar R
J Crohns Colitis; 2014 Nov; 8(11):1407-16. PubMed ID: 24874893
[TBL] [Abstract][Full Text] [Related]
8. Sarcoidosis complicating treatment with adalimumab for Crohn's disease.
McDonnell MJ; Rutherford RM; O'Regan A
J Crohns Colitis; 2014 Sep; 8(9):1140-1. PubMed ID: 24631310
[No Abstract] [Full Text] [Related]
9. [Level of adalimumab and its antibody titers define the effectiveness of the biological (anticytokine) therapy in Crohn's disease].
Lazebnik LB; Sagynbaeva VÉ
Eksp Klin Gastroenterol; 2013; (7):18-22. PubMed ID: 24772870
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy and safety of Adalimumab in Crohn's disease].
Serghini M; Haddad W; Jeddi H; Karoui S; Ben Mustapha N; Kallel L; Fekih M; Matri S; Boubaker J; Filali A
Tunis Med; 2012 Feb; 90(2):101-7. PubMed ID: 22407620
[TBL] [Abstract][Full Text] [Related]
11. Probable diffuse retinopathy caused by adalimumab in a patient with Crohn's disease.
Marticorena-Álvarez P; Chaparro M; Pérez-Casas A; Muriel-Herrero A; Gisbert JP
J Crohns Colitis; 2012 Oct; 6(9):950-3. PubMed ID: 22537636
[TBL] [Abstract][Full Text] [Related]
12. Exploring the use of adalimumab for patients with moderate Crohn's disease: subanalyses from induction and maintenance trials.
Sandborn WJ; Colombel JF; Panés J; Castillo M; Robinson AM; Zhou Q; Yang M; Thakkar R
J Crohns Colitis; 2013 Dec; 7(12):958-67. PubMed ID: 23517933
[TBL] [Abstract][Full Text] [Related]
13. [Oligosymptomatic alimentary tract perforation in course of Crohn's disease in patient treated with anti-TNF alfa antibodies].
Jałocha Ł; Wojtuń S; Wojtkowiak M; Błaszak A; Dyrla P; Gil J
Pol Merkur Lekarski; 2009 May; 26(155):491-2. PubMed ID: 19606707
[TBL] [Abstract][Full Text] [Related]
14. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial.
Van Assche G; Vermeire S; Ballet V; Gabriels F; Noman M; D'Haens G; Claessens C; Humblet E; Vande Casteele N; Gils A; Rutgeerts P
Gut; 2012 Feb; 61(2):229-34. PubMed ID: 21948942
[TBL] [Abstract][Full Text] [Related]
15. Infliximab and adalimumab-induced psoriasis in Crohn's disease: a paradoxical side effect.
Iborra M; Beltrán B; Bastida G; Aguas M; Nos P
J Crohns Colitis; 2011 Apr; 5(2):157-61. PubMed ID: 21453886
[TBL] [Abstract][Full Text] [Related]
16. Listeria monocytogenes infection in Crohn's disease treated with adalimumab.
Willson KJ; Jacob A; Shetti MP; Bhatia R; Yee K; Osler W
Med J Aust; 2012 Oct; 197(8):466-7. PubMed ID: 23072245
[No Abstract] [Full Text] [Related]
17. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.
Sandborn WJ; Hanauer SB; Rutgeerts P; Fedorak RN; Lukas M; MacIntosh DG; Panaccione R; Wolf D; Kent JD; Bittle B; Li J; Pollack PF
Gut; 2007 Sep; 56(9):1232-9. PubMed ID: 17299059
[TBL] [Abstract][Full Text] [Related]
18. [Adalimumab for the treatment of Crohn's disease - consensus paper of the Working Group "chronic inflammatory bowel diseases" of the Austrian Society for Gastroenterology and Hepatology].
Reinisch W; Haas T; Kaser A; Petritsch W; Vogelsang H; Feichtenschlager T; Novacek G; Siebert F; Tilg H; Knoflach P
Z Gastroenterol; 2009 Apr; 47(4):372-80. PubMed ID: 19358065
[TBL] [Abstract][Full Text] [Related]
19. [Effectiveness of anti-TNF alpha antibodies in treatment of fistulizing Crohn's disease].
Rozpondek P; Zwolińska-Wcisło M; Przybylska M; Mach T
Przegl Lek; 2011; 68(9):602-5. PubMed ID: 22335009
[TBL] [Abstract][Full Text] [Related]
20. Severe myalgia associated with adalimumab treatment in a patient with Crohn's disease.
Hinojosa J; Borrás-Blasco J; Maroto N; Rosique-Robles JD; Alos R; Casterá ME
Ann Pharmacother; 2008 Jul; 42(7):1130-3. PubMed ID: 18492783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
